Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955588 | 0.85 | KDR (0.54) | KDRMETMKNK1EGFRTNNI3K | |
| SCHEMBL4045792 | 0.84 | MKNK1 (0.76) | FGFR1KDRMKNK1EGFRMAPK1 | |
| SCHEMBL12908954 | 0.84 | KDR (0.56) | FGFR1KDRMETMKNK1EGFR | |
| Hydrochloric Acid SCHEMBL938925 | 0.83 | KDR (0.55) | FGFR1KDRMETMKNK1EGFR | |
| SCHEMBL938557 | 0.82 | KDR (0.65) | FGFR1KDRMETMKNK1EGFR | |
| SCHEMBL12908964 | 0.81 | KDR (0.57) | FGFR1KDRMETMKNK1EGFR | |
| Hydrochloric Acid SCHEMBL939888 | 0.81 | KDR (0.56) | FGFR1KDRMETMKNK1EGFR | |
| SCHEMBL12908963 | 0.79 | KDR (0.57) | FGFR1KDRMETMKNK1EGFR | |
| SCHEMBL12944795 | 0.79 | MAPT (0.62) | FGFR1KDRMETMKNK1EGFR | |
| SCHEMBL938202 | 0.79 | EGFR (0.74) | FGFR1KDRMETMKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | FGFR1 3381/4885KDR 4233/4885MET 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.